Like most investors, I assess Gale based on four important aspects of the company.
(1) The biotechology: Gale has NeuVax which is at Phase 3 with SAP, Phase 2b (NeuVax+Herceptin). The likelihood of getting FDA approval is very high based on known safety profiles, high effective rates and very low side effects. We have Folate Binding Protein.
(2) Markets: When FDA approves NeuVax (patented) the market is huge and it can move Gale reaching $4.0 billion sale company. Abstral should generate revenue reaching $60 millions.
(3) Finance: Revenue from Abstral, according to most experts, should be able to finance clinical trials of NeuVax and FBP beyond 2015. As a result, dilution would not be needed.
(4) Management: I have followed Gale for over 2 years and this is the weakest aspect of the company. While the CEO concentrate most of his energy in developing NeuVax, he has not earn my confidence. Because, I have not found strong evidence that he cares for his shareholders, especially when he draws $1.0 million annual salary. I have followed all of his presentations on medical or financial conferences, and frankly, I am not impressed. He is either not willing or not capable in advancing shareholder interests. I have seen several CEOs on different drug developmental companies who handle pure speculators and stock manipulators very well and hence the price movements of these companies are a lot less volatile than what Gale has been experiencing. Good and positive PRs from Gale to keep investors well informed on the positive aspects have been non-existent. Investors perceive Gale as risky primarily because of weak management. There is much room for improvement! Management can buy a good number of Gale shares and that should dispel a lot of negative attacks and put the speculators and stock manipulators to "you know where"!
Well said, unfortunately, especially #4. The CEO needs to be the "cheer leader" and spokesperson for the company (employees), shareholders, etc.... and instill confidence about the company (and its future) in the investment community, and Ahn does not do that very well, IMO.